Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $592 thousand versus the consensus estimate of $340 thousand.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.